Targeted therapies could exploit unique metabolic features of pancreatic cancer cells Probing the unique biology of human pancreatic cancer cells in a laboratory has yielded unexpected insights of a weakness that can be used against the cells to kill them. Led by Princess Margaret Cancer Centre (PM) Scientist Dr. Marianne Koritzinsky, researchers showed that about half of patient-derived pancreatic cancer cell lines are highly dependent or "addicted" to the protein peroxiredoxin 4 (PRDX4), as a result of the altered metabolic state of the cancer cell. This addiction is vital for the cancer cell's survival, thereby also making it a precise, potential target against the cancer.